SCHEMBL7015846

SCHEMBL7015846

C[C@H](Nc1nc(-c2ccccc2CO)cc(-n2cnc3cc(-c4ccnc(N)n4)ccc32)n1)c1cccc([N+](=O)[O-])c1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LCK P06239 12/20 0.58
PLK1 P53350 2/20 0.37
CYP3A4 P08684 1/20 0.37
PLK3 Q9H4B4 1/20 0.37
PFKFB3 Q16875 1/20 0.36
MKNK1 Q9BUB5 1/20 0.34
MKNK2 Q9HBH9 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HTT P42858 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
JAK2 O60674 1/20 0.34
JAK3 P52333 1/20 0.34
CLK1 P49759 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7016544 0.91 LCK (0.61) LCKPLK1CYP3A4PLK3PFKFB3
SCHEMBL7568847 0.90 LCK (0.71) LCKPLK1CYP3A4PLK3MKNK1
SCHEMBL7020588 0.90 LCK (0.71) LCKPLK1CYP3A4PLK3MKNK1
SCHEMBL7018434 0.85 LCK (0.76) LCKPLK1CYP3A4PLK3PFKFB3
SCHEMBL7509006 0.85 LCK (0.43) LCKPLK1CYP3A4PLK3MKNK1
SCHEMBL7018679 0.81 LCK (0.55) LCKPLK1CYP3A4PLK3MKNK2
SCHEMBL7017083 0.80 LCK (0.52) LCKPLK1PLK3MKNK1MKNK2
SCHEMBL7575747 0.80 LCK (0.76) LCKPLK1CYP3A4PLK3KDM4E
SCHEMBL7016254 0.80 LCK (0.76) LCKPLK1CYP3A4PLK3KDM4E
SCHEMBL7024612 0.79 LCK (0.70) LCKPLK1CYP3A4PLK3MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1206265-B1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2003-11-12 EP claimed
US-6498165-B1 PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS MERCK & CO., INC. 2002-12-24 US claimed
EP-1206265-B1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2003-11-12 EP disclosed
US-6498165-B1 PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS MERCK & CO., INC. 2002-12-24 US disclosed